# Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

> **NCT05493293** · PHASE2 · TERMINATED · sponsor: **Neurocrine Biosciences** · enrollment: 82 (actual)

## Conditions studied

- Focal Onset Seizure
- Focal Onset Epilepsy

## Interventions

- **DRUG:** NBI-921352

## Key facts

- **NCT ID:** NCT05493293
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-09
- **Primary completion:** 2024-03-11
- **Final completion:** 2024-03-11
- **Target enrollment:** 82 (ACTUAL)
- **Why stopped:** The long-term extension study was terminated because the parent study NBI-921352-FOS2021 (NCT05159908) failed to meet its primary endpoint.
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05493293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05493293, "Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05493293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*